Pharis Mohideen, M.D.
Chief Medical Officer
Dr. Pharis Mohideen has extensive experience across the full spectrum of drug development in a broad range of therapeutic areas, including orphan, endocrine and metabolic diseases. Prior to Millendo, Dr. Mohideen was vice president of clinical development at Shionogi Inc., a global pharmaceutical company. There, he designed and led the company through its first full Phase 3 development program outside of Japan, and was a core member of the team that gained approval of ospemifene. Previously, he was global clinical program head at Novartis Oncology, where he was responsible for leading all clinical development and registration activities for three key compounds, including pasireotide, a second generation somatostatin analogue for rare endocrine indications like Cushing’s disease, acromegaly and neuroendocrine tumors. Dr. Mohideen began his career at Bristol-Myers Squibb in a global clinical development role working in diabetes and metabolic diseases. Prior to joining the pharmaceutical industry, Dr. Mohideen maintained an academic position at the University of Hawaii, department of internal medicine (endocrinology), where he treated patients and served as an investigator on multiple pharmaceutical-sponsored clinical trials.
Dr. Mohideen holds an M.D., M.S. in human physiology and B.A. in biology from the University of Hawaii. He also holds an M.S. in clinical investigation from Vanderbilt University.